Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4

Paul T. Golumbek, Audrey J. Lazenby, Hyam I. Levitsky, Liz M. Jaffee, Hajime Karasuyama, Mitzi Baker, Drew M. Pardoll

Research output: Contribution to journalArticle

690 Citations (Scopus)

Abstract

The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

Original languageEnglish (US)
Pages (from-to)713-716
Number of pages4
JournalScience
Volume254
Issue number5032
DOIs
StatePublished - Jan 1 1991

Fingerprint

Renal Cell Carcinoma
Interleukin-4
Neoplasms
Immunity
Therapeutics
T-Lymphocytes
Lymphokines
Immunotherapy
Kidney
Antigens
Injections
Genes

ASJC Scopus subject areas

  • General

Cite this

Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254(5032), 713-716. https://doi.org/10.1126/science.1948050

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. / Golumbek, Paul T.; Lazenby, Audrey J.; Levitsky, Hyam I.; Jaffee, Liz M.; Karasuyama, Hajime; Baker, Mitzi; Pardoll, Drew M.

In: Science, Vol. 254, No. 5032, 01.01.1991, p. 713-716.

Research output: Contribution to journalArticle

Golumbek, PT, Lazenby, AJ, Levitsky, HI, Jaffee, LM, Karasuyama, H, Baker, M & Pardoll, DM 1991, 'Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4', Science, vol. 254, no. 5032, pp. 713-716. https://doi.org/10.1126/science.1948050
Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Jan 1;254(5032):713-716. https://doi.org/10.1126/science.1948050
Golumbek, Paul T. ; Lazenby, Audrey J. ; Levitsky, Hyam I. ; Jaffee, Liz M. ; Karasuyama, Hajime ; Baker, Mitzi ; Pardoll, Drew M. / Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. In: Science. 1991 ; Vol. 254, No. 5032. pp. 713-716.
@article{d53c1bfee03f4b478b2d1dc7bf3443b6,
title = "Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4",
abstract = "The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.",
author = "Golumbek, {Paul T.} and Lazenby, {Audrey J.} and Levitsky, {Hyam I.} and Jaffee, {Liz M.} and Hajime Karasuyama and Mitzi Baker and Pardoll, {Drew M.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1126/science.1948050",
language = "English (US)",
volume = "254",
pages = "713--716",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5032",

}

TY - JOUR

T1 - Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4

AU - Golumbek, Paul T.

AU - Lazenby, Audrey J.

AU - Levitsky, Hyam I.

AU - Jaffee, Liz M.

AU - Karasuyama, Hajime

AU - Baker, Mitzi

AU - Pardoll, Drew M.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

AB - The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026331269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026331269&partnerID=8YFLogxK

U2 - 10.1126/science.1948050

DO - 10.1126/science.1948050

M3 - Article

C2 - 1948050

AN - SCOPUS:0026331269

VL - 254

SP - 713

EP - 716

JO - Science

JF - Science

SN - 0036-8075

IS - 5032

ER -